Pfizer Inc. announced that the first participant has been dosed in the Phase III CIFFREO study, which will evaluate the efficacy and safety of investigational gene therapy candidate PF-06939926 in boys with Duchenne muscular dystrophy.
[Pfizer Inc.]
0